Thrombectomy Devices Market - Strategies Adopted by Top Market Players
According to research report thrombectomy
devices market is estimated to reach USD 1.45 billion by 2022;
growing at a CAGR of 6.7% during the forecast period.
The key players focused on various strategies such as
product launches and enhancements; agreements and collaborations; strategic
acquisitions; and expansions to increase their shares in the global
thrombectomy devices market. Product launches & enhancements is the strategy adopted by major industry
players to achieve the desired market growth during 2013-2017. This strategy was adopted by Stryker Corporation
(U.S.), Medtronic plc (Ireland), Boston Scientific Corporation (U.S.), Johnson
& Johnson (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.),
Spectranetics Corporation (U.S.), Edwards Lifesciences Corporation (U.S.),
Argon Medical Devices, Inc. (U.S.), and Teleflex Incorporated (U.S.).
Apart from product launches and enhancements, many prominent players also
adopted agreements and collaborations as their key growth strategy to strengthen
their market presence, enhance their R&D capabilities, and to expand their
distribution networks to generate additional demand by sensitizing end users
through an increase in availability of
thrombectomy devices.
Download Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222966801
Stryker Corporation held the leading position in the market
in 2016. The company offers its thrombectomy devices through the
Neurotechnology & Spine segment. The company has a strong presence in North
America, Europe, the Middle East, Africa, Asia-Pacific and other countries. The
company has more than 30 manufacturing facilities in countries such as the
U.S., China, Turkey, Germany, Ireland, Switzerland, and France. It primarily
focuses on growth strategies such as product development &
commercialization, acquisitions, and market expansions. The market has
witnessed several product launches & commercialization, expansions, and acquisitions
by Stryker Corporation (U.S.) in the last three years. For instance, in 2016,
the company commercialized thrombectomy devices such as Trevo Provue retriever and
Trevo XP ProVue retriever, the establishment of its European headquarters in
Amsterdam (Netherlands), in 2015, and the acquisition of Trauson Holdings
Company Limited (China) in 2013. These developments strengthened its R&D
capabilities and expanded its product portfolio in the market.
Medtronic plc is one of the prominent players in the
market, in 2016. The company has a strong foothold in the market with a broad
range of thrombectomy products. The company has a strong geographic presence
across Asia-Pacific, Eastern Europe, Latin America, the Middle East &
Africa, Central Asia, Western Europe, South Asia, and North America. To
strengthen its current position and to gain a larger share in the market, the company aggressively focuses
on growth strategies such as acquisitions and market expansions. During
2012–2016, the company established its training and research facility—Covidien
Center of Innovation Brazil—in Brazil and its R&D, training, and education
center—Covidien Center of Innovation Korea—in South Korea to enhance its
R&D capabilities and expand its product portfolio and market presence in
the market. The company also focuses on product commercialization as its
business strategy. It commercialized thrombectomy devices such as the Solitaire
stent retriever device in 2016 and Solitaire revascularization device in 2012.
Know more: https://www.marketsandmarkets.com/Market-Reports/thrombectomy-devices-market-222966801.html
Contact:
Mr. Shelly Singh
MarketsandMarkets™
INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com
Comments
Post a Comment